Nascent Biotech Inc. (NBIO)

[Robertscott]

Shares are tight here

[BlazingStocks]

Definitely looking thin... Let's see some Phase II News.

[BlazingStocks]

Holding steady on low volume... Seems to be the bottom.

$NBIO

[Robertscott]

I love the fundamentals here

[Robertscott]

Time to rebound NBIO

[jedijazz]

$NBIO Nascent Biotech, Inc. (NBIO)
OTCMKTS: NBIO https://stockanalysis.com/stocks/nbio/

[jedijazz]

$NBIO has also been actively shoring up its IP stronghold, recently announcing a move, in partnership with China based BioRay Pharmaceutical, to terminate the license agreement entered into on March 31, 2021.

With the move, Nascent regained its worldwide marketing and distribution rights previously licensed to BioRay. Management has clearly decided that regaining worldwide rights will put NBIO and its shareholders in a stronger position going forward.

This is an unambiguously positive development.

https://www.streetinsider.com/Press+Releases/Why+NBIO+is+a+Biotech+Bargain+Basement+Deal+with+Underappreciated+Potential/21893288.html

[jedijazz]

You can see how thin $NBIO is on level 2. Ready for a breakout!

[jedijazz]

$NBIO 's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com

[Robertscott]

This could be a good signal to watch for NBIO
Shoring Up IP Control

A further likely positive signal is the fact that NBIO has also been actively shoring up its IP stronghold, recently announcing a move, in partnership with China based BioRay Pharmaceutical, to terminate the license agreement entered into on March 31, 2021.

[Robertscott]

Check out NBIO's website www.nascentbiotech.com.

[Robertscott]

This could be a big one

NBIO's flagship drug is Pritumumab (PTB), a natural human antibody that binds to cell surface Vimentin (also referred to as ectodomain vimentin), which is a protein expressed on the surface of epithelial cancers.

[jedijazz]

NBIO recently presented its Phase I data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation.

If you are interested, the company noted in a recent release that its abstract can be located and surveyed on its website(www.nascentbiotech.com) Or at https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2053.

[jedijazz]

$NBIO Nascent Biotech Inc. is an emerging player in the $4 billion oncology drug development space with a legitimate IP asset possibly heading into Phase 2 clinical research for its first flagship pipeline asset. https://www.benzinga.com/pressreleases/23/07/33177689/why-nbio-is-a-biotech-bargain-basement-deal-with-underappreciated-potential

[Robertscott]

Looks like only shares traded are people buying right now. No selling NBIO

[Robertscott]

Ask time NBIO

[jedijazz]

$NBIO .05's are thin to a new HOD!

[BlazingStocks]

Looking better...$NBIO is in the course of its development and commercialization process for its flagship cancer treatment...Naturally, once promising data begins to get public attention, the cat will be out of the bag and shares will be tough to chase.
https://www.benzinga.com/pressreleases/23/07/33177689/why-nbio-is-a-biotech-bargain-basement-deal-with-underappreciated-potential

[Robertscott]

NBIO is in the course of its development and commercialization process for its flagship cancer treatment suggests the potential for speculative interest starting to enter the picture.

[jedijazz]

$NBIO Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets cell surface Vimentin (ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is a targeted immunotherapy that binds to the tumor via cell surface vimentin and recruits the host immune system to eliminate cancer cells.

About Nascent Biotech

Nascent Biotech, Inc. is a clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a human monoclonal Antibody (Mab) that is progressing to Phase 2 clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

[jedijazz]

$NBIO very positive sentiment here!

[BlazingStocks]

Thank you for sharing that article... Been watching $NBIO closely to add shares.

[Robertscott]

Spread just tightened NBIO

[jedijazz]

$NBIO Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
NORTH PALM BEACH, FL / ACCESSWIRE / June 7, 2023 / Nascent Biotech, Inc. (NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space presented their Phase I Clinical Data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation. The abstract may be viewed on the Company web site www.nascentbiotech.com. The data is also available at https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2053.

[budfoxfun]

.05's super thin

[budfoxfun]

Low floater, won't take much here for a breakout!

[jedijazz]

$NBIO is in the course of its development and commercialization process for its flagship cancer treatment suggests the potential for speculative interest starting to enter the picture. Naturally, once promising data begins to get public attention, the cat will be out of the bag and shares will be tough to chase.

[jedijazz]

Why $NBIO is a Biotech Bargain Basement Deal with Underappreciated Potential https://www.benzinga.com/pressreleases/23/07/33177689/why-nbio-is-a-biotech-bargain-basement-deal-with-underappreciated-potential

[Robertscott]

Looking thin this morning NBIO

[Robertscott]

This is when new star drug assets have the opportunity to shine in the public eye for the first time as early data from Phase 2 research tends to have implications for future market potential or the likelihood of eventual full FDA approval and commercial ROI. NBIO

[budfoxfun]

.05 ready to go!

[Robertscott]

The share price of a stock isn't a very important number. Investment outcomes are logarithmic. It's all about percentage change. And low-priced stocks with legitimate IP, assets, or operations and a plausible path to notable growth shouldn't be dismissed out of hand. This is especially true of biotechnology stocks in our experience.

NBIO provides a good example of this potential.

[Robertscott]

$NBIO Nascent Biotech Inc. is an emerging player in the $4 billion oncology drug development space with a legitimate IP asset possibly heading into Phase 2 clinical research for its first flagship pipeline asset.

[budfoxfun]

Nascent Biotech Inc. NBIO is an emerging player in the $4 billion oncology drug development space with a legitimate IP asset possibly heading into Phase 2 clinical research for its first flagship pipeline asset. Besides the good news that it appears to have successfully navigated Phase 1 research, this stage of development is of particular interest to institutional money managers involved in the biotech space. https://www.benzinga.com/pressreleases/23/07/33177689/why-nbio-is-a-biotech-bargain-basement-deal-with-underappreciated-potential

[LearningEveryTrade]

after the ASCO 2023 Poster reveal, BioRay ditched them (badly disguised as 'regains world-wide rights') and they are not giving them 2.5M for these poor results, not wonder they did not develop it themselves; they already knew it was not effective. Begs the question.... where on Earth will they get money to continue? Perhaps that letter to shareholders about needing to raise money (18M) means an offering soon = dilution. IMHO.
https://finance.yahoo.com/news/nascent-biotech-regains-worldwide-rights-214500439.html
https://www.nascentbiotech.com/a-letter-to-nascent-biotech-shareholders-may-1-2023/

[Aa5]

15 patients in recent clinical trial and "One partial response showed nearly a 98.0% and 40.8% reduction in 2 tumor lesions for 17 months on study. "
Sounds good to me.

The clinical in Japan years ago showed 65% bioactivity. (Per the Marble Arch Report)

Looking forward to goring forward.

[BlazingStocks]

Thank you, good luck to you and everyone here.

$NBIO

[FairviewInvestor]

1st buy after selling on that big move August. .0395 Lotto...

[Aa5]

"One partial response showed nearly a 98.0% and 40.8% reduction in 2 tumor lesions for 17 months on study. "

I wish we had more information about the Phase 1 clinical trial. Share price dropping though.

[gladeshawk]

I agree. I have shares. I just think there will be continued "dips" down to the mid .03s and bring my .041 avg. down a bit. GLTU and GLTA going forward. HAWK

[BlazingStocks]

It's a great opportunity to load at these prices because as testing progresses, the price should move up accordingly.

[gladeshawk]

I have bids in down into the .03s. Someone always seems to just dump shares. After, higher price in the future. HAWK

[BlazingStocks]

Nice opportunity to add at these prices... Been accumulating for a while.

$NBIO

[budfoxfun]

$NBIO The abstract may be viewed on the Company web site www.nascentbiotech.com. The data is also available at https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2053.

https://finance.yahoo.com/news/nascent-biotech-phase-clinical-data-120000403.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[BlazingStocks]

$NBIO - presented their Phase I therapeutic antibody Pritumumab (PTB) Clinical Data at the American Society of Clinical Oncology (ASCO) meeting in Chicago in a poster presentation.

The data is available at https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2053.

[budfoxfun]

.042's thinning here!

[BlazingStocks]

$NBIO trading about half of its 10-day average volume as we trade in lunchtime... let's see if volume picks up during Power Hour.

[BlazingStocks]

Absolutely... Phase II could be really soon based off those good results.

$NBIO

[BlazingStocks]

Sounds like the data looks really good... I'm expecting more announcements in the short term.

$NBIO

[budfoxfun]

Under .05 a steal here!